A Novel Approach to Overcome T Cell Exhaustion for Enhanced Anti-Tumor Activity

Technology Description

Our cutting-edge therapeutic platform utilizes CRISPR/Cas gene-editing technology to engineer modified T-cells with superior cytotoxicity and endurance, even under chronic tumor stimulation. This innovative approach addresses the critical challenge of T-cell exhaustion, which limits the efficacy of conventional immuno-oncology therapies. The platform is highly versatile, enabling the modification of various T-cell subtypes, including CD8+ T cells, CD4+ T cells, gamma delta T cells, and memory T cells, to create a robust and adaptive anti-tumor response.

Competitive Advantages

• Enhanced Functionality: Modified T-cells exhibit improved effector function and persistence, overcoming the limitations of T-cell exhaustion in chronic tumor environments.
• Precision Gene Editing: Leveraging CRISPR/Cas technology ensures precise, efficient, and targeted modifications, optimizing T-cell performance.
• Versatile Platform: The ability to modify multiple T-cell subtypes allows tailored therapies for diverse tumor profiles and indications.
• Preclinical Proof-of-Concept: Demonstrated increased tumor killing and persistence in HER2 and BCMA CAR-T in vitro models, along with enhanced multiple myeloma burden control in BCMA CAR-T in vivo models.

Stage of Development

Preclinical proof of concept

Related Materials

Patent Status

Patent Pending